Drug
Orismilast clinical trials
Also written LEO 32731.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
Studies by the year they started
12 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 1
LEO Pharma (9) · UNION therapeutics (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Gregor Jemec (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses orismilast is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study to Assess the Efficacy and Safety of Orismilast in PsoriasisCompletedPhase 2UNION therapeuticsNCT05190419Written as Orismilast modified release tablets
- A Study of IBI353 (Orismilast) in Chinese Healthy AdultsCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05490316Written as IBI353 (Orismilast)
- Orismilast for the Treatment of Mild to Severe Hidradenitis SuppurativaStatus unknownPhase 2Gregor JemecNCT04982432Written as Orismilast
- Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.CompletedPhase 1LEO PharmaNCT03231124Written as LEO 32731
- A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy PeopleCompletedPhase 1LEO PharmaNCT03812198Written as LEO 32731 modified release tablet
- Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and MidazolamCompletedPhase 1LEO PharmaNCT03126578Written as LEO 32731
- LEO 32731 for the Treatment of Moderate to Severe Psoriasis VulgarisCompletedPhase 2LEO PharmaNCT02888236Written as LEO 32731
- LEO 32731 - A Phase I Study in Healthy SubjectsCompletedPhase 1LEO PharmaNCT02514694Written as LEO32731
- An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)CompletedPhase 1LEO PharmaNCT02496546Written as LEO 32731 cream
- A Phase I Study With LEO 32731 and Midazolam in Healthy Male SubjectsTerminatedPhase 1LEO PharmaNCT02753218Written as LEO 32731
- LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy SubjectsCompletedPhase 1LEO PharmaNCT02126371Written as LEO32731
- LEO 32731 - A Study in Healthy Male SubjectsCompletedPhase 1LEO PharmaNCT01310049Written as LEO 32731
Codes
What other systems call orismilast · ClinicalTrials.gg INT016950
- UNII (FDA) JH1CX8SG5VORISMILASTOne source FDA
- NCI Thesaurus C175833OrismilastOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JH1CX8SG5V | ORISMILAST | One source FDA |
| NCI Thesaurus | C175833 | Orismilast | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.